Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Kala Pharmaceuticals ( (KALA) ) is now available.
Kala Pharmaceuticals, a company in the biopharmaceutical industry, announced the appointment of Todd Bazemore as its Chief Executive Officer on August 29, 2025. Mr. Bazemore, who has been serving as the interim CEO since February 2025, will also continue as President and has been elected as a Class II director on the Board of Directors. His extensive experience in the pharmaceutical sector includes roles at Santhera Pharmaceuticals and Dyax Corp. The appointment includes a revised offer letter detailing his salary, bonus eligibility, and severance benefits, as well as a stock option grant.
The most recent analyst rating on (KALA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Kala Pharmaceuticals stock, see the KALA Stock Forecast page.
Spark’s Take on KALA Stock
According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.
Kala Pharmaceuticals faces significant financial difficulties, marked by declining revenues and heavy reliance on debt, which pose serious risks. The technical analysis reflects a strong downtrend, with the stock being oversold, adding to the negative outlook. Valuation is unattractive due to negative earnings and the lack of a dividend, further weighing down the stock’s appeal.
To see Spark’s full report on KALA stock, click here.
More about Kala Pharmaceuticals
Average Trading Volume: 141,901
Technical Sentiment Signal: Buy
Current Market Cap: $78.78M
For an in-depth examination of KALA stock, go to TipRanks’ Overview page.